AI-powered search

Dupilumab Beneficial for Patients With Hand, Foot Atopic Dermatitis

Significantly more patients achieved Hand and Foot Investigator's Global Assessment score of 0 or 1

By Dermsquared Editorial Team | May 15, 2024

WEDNESDAY, May 15, 2024 -- Dupilumab monotherapy is efficacious and safe for patients with atopic hand and/or foot dermatitis, according to a study published in the June issue of the Journal of the American Academy of Dermatology.

Eric L. Simpson, M.D., from the Oregon Health & Science University in Portland, and colleagues examined the efficacy and safety of dupilumab in atopic hand and/or foot dermatitis in a phase 3 study involving adults and adolescents with moderate-to-severe atopic dermatitis (106 adults and 27 adolescents). Participants were randomly assigned to dupilumab monotherapy or matched placebo (67 and 66 patients, respectively). The proportion of patients achieving a Hand and Foot Investigator's Global Assessment score of 0 or 1 at week 16 was examined as the primary end point.

The researchers found that significantly more patients receiving dupilumab versus placebo achieved a Hand and Foot Investigator's Global Assessment score of 0 or 1 (27 versus 11 [40.3 versus 16.7 percent]). All other prespecified end points were met and safety was consistent with the known atopic dermatitis dupilumab profile.

"This study supports dupilumab as a novel efficacious systemic therapy for moderate-to-severe atopic hand and/or foot dermatitis," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Sanofi and Regeneron, which manufacture dupilumab and funded the study.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved